METHOD OF COMPLEX TREATMENT OF PATIENTS WITH PURULONECROTIC COMPLICATIONS OF DIABETIC FOOT SYNDROME Russian patent published in 2020 - IPC A61B17/00 A61M1/00 A61K31/76 A61K31/557 A61K38/43 A61P41/00 A61F13/02 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to surgery, can be used to accelerate the healing of postoperative foot wounds, activate local immunity, increasing regenerative activity of involved tissues, preventing microthrombosis of peripheral arterial bed in patients with purulonecrotic complications of diabetic foot syndrome. Treatment is conducted in three phases. At the first stage, the wound of the foot is sealed from the external environment by the application of a sterile sponge and an adhesive film, constant negative pressure of 100 mm Hg is created above the wound with the port and VIT Medical portable vacuum aspiration device for 10 days. Simultaneously, drug-induced treatment is carried out, including intravenous drop introduction of Vessel DUE F 600 LE per 200 ml of 0.9 % sodium chloride solution per day, introduction of Vasaprostan 60 mcg once a day intravenously drop-by-drop on 200 ml of 0.9 % sodium chloride solution and oral administration of Trombovazim 800 units twice a day. At the second stage, oscillations of negative pressure over the wound are created by automatic change of the pressure level from 100 to 20 mm Hg and back, with change of 20 mm Hg per hour during a day for six to eight days. At the same time, Vessel DUE F 250 LE 1 capsule is taken orally twice a day, Trombovazim 800 units twice a day. At the third stage, the local foot wound treatment is performed with the "G-Derm" histoequivalent-bioplastic material with a dressing interval of two to three days, which is moistened twice a day with 0.9 % sodium chloride solution, in a combination with oral administration of Vessel DUE F 250 LE 1 capsule twice a day with a total course of 8 weeks, oral administration of Trombovazim 800 units twice a day with a total course of twenty days. After completing receiving Trombovazim oral administration of Xarelto 2.5 mg twice a day, course 12-24 weeks.

EFFECT: method enables higher effectiveness and reduced length of treatment of patients with purulonecrotic complications of diabetic foot syndrome ensured by a combination of methods of the declared method.

1 cl, 1 ex